MX2016012483A - Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. - Google Patents
Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos.Info
- Publication number
- MX2016012483A MX2016012483A MX2016012483A MX2016012483A MX2016012483A MX 2016012483 A MX2016012483 A MX 2016012483A MX 2016012483 A MX2016012483 A MX 2016012483A MX 2016012483 A MX2016012483 A MX 2016012483A MX 2016012483 A MX2016012483 A MX 2016012483A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- compositions
- methods
- disease
- trka kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se dirige a compuestos heteroaril benzamida bicíclicos de fórmula (I) (ver Fórmula) que son inhibidores de la proteína quinasa de la familia quinasa relacionada con tropomiosina (Trk), y por lo tanto son útiles en el tratamiento del dolor, inflamación, cáncer, restenosis, aterosclerosis, psoriasis, trombosis, una enfermedad, trastorno, lesión, o mal funcionamiento en relación con dismielinación o desmielinación o una enfermedad o trastorno asociado con actividades anormales del receptor TrkA del factor de crecimiento nervioso (NGF).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2014/074143 WO2015143652A1 (en) | 2014-03-26 | 2014-03-26 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
PCT/US2015/022004 WO2015148373A2 (en) | 2014-03-26 | 2015-03-23 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016012483A true MX2016012483A (es) | 2016-12-16 |
Family
ID=54193893
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016012481A MX2016012481A (es) | 2014-03-26 | 2015-03-23 | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. |
MX2016012483A MX2016012483A (es) | 2014-03-26 | 2015-03-23 | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016012481A MX2016012481A (es) | 2014-03-26 | 2015-03-23 | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. |
Country Status (10)
Country | Link |
---|---|
US (2) | US9862716B2 (es) |
EP (2) | EP3122345B1 (es) |
JP (2) | JP2017508766A (es) |
KR (2) | KR20160132114A (es) |
CN (2) | CN106456582A (es) |
AU (2) | AU2015236438A1 (es) |
CA (2) | CA2942957A1 (es) |
MX (2) | MX2016012481A (es) |
RU (2) | RU2016141645A (es) |
WO (3) | WO2015143652A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
WO2018236856A1 (en) * | 2017-06-19 | 2018-12-27 | University Of Maryland, Baltimore | CAR ACTIVATING AGENTS FOR THE TREATMENT OF CANCER BASED ON CYCLOPHOSPHAMIDE |
WO2019070943A1 (en) * | 2017-10-04 | 2019-04-11 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULE INHIBITION OF SALL4 TRANSCRIPTION FACTOR AND USES THEREOF |
JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
TW201936194A (zh) * | 2017-12-15 | 2019-09-16 | 美商金字塔生技公司 | 肌旋蛋白激酶抑制劑 |
IL298250A (en) | 2018-04-12 | 2023-01-01 | Bayer Ag | n-(cyclopropylmethyl)-5-(methylsulfonyl)-n-{1-[1-(pyrimidin-2-yl)-h1-1, 2, 4-triazol-5-yl]ethyl}benzamide derivatives and pyridine-carboxamide derivatives Compatible as pest killers |
KR102129114B1 (ko) * | 2018-07-26 | 2020-07-02 | 주식회사 온코파마텍 | TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물 |
WO2020038415A1 (en) * | 2018-08-22 | 2020-02-27 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
CN111269233A (zh) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021069567A1 (en) | 2019-10-09 | 2021-04-15 | Bayer Aktiengesellschaft | Novel heteroaryl-triazole compounds as pesticides |
JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
TW202134226A (zh) | 2019-11-18 | 2021-09-16 | 德商拜耳廠股份有限公司 | 作為殺蟲劑之新穎雜芳基-三唑化合物 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN115916771A (zh) * | 2020-04-02 | 2023-04-04 | 浙江华海药业股份有限公司 | 多靶点的抗肿瘤化合物及其制备方法和应用 |
TW202210467A (zh) | 2020-05-28 | 2022-03-16 | 美商美國禮來大藥廠 | TrkA抑制劑 |
CN113666862A (zh) * | 2021-08-18 | 2021-11-19 | 山东大学 | 一种通过镍催化不对称硝化反应制备手性3-硝基吲哚类化合物的方法 |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB599834A (en) * | 1943-04-08 | 1948-03-22 | Francolor Sa | Improvements in or relating to the manufacture of azodyestuffs |
CN1046730C (zh) * | 1994-06-21 | 1999-11-24 | 株式会社大塚制药工场 | 吡唑并[1,5-a]嘧啶衍生物 |
IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
DE19946322A1 (de) | 1999-09-28 | 2001-03-29 | Bayer Ag | Verfahren zur Konditionierung von Ionenaustauscherharzen |
FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
WO2001081345A1 (fr) * | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Composes d'amides aromatiques |
US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
KR100713137B1 (ko) * | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
EP1820503B1 (en) * | 2001-09-26 | 2012-02-22 | Pfizer Italia S.r.l. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
US20030144518A1 (en) * | 2001-12-07 | 2003-07-31 | The Procter & Gamble Company | Process for preparing 3-acylamino-imidazo[1,2-a]pyridines |
JP2003231687A (ja) * | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
WO2003068773A1 (en) * | 2002-02-12 | 2003-08-21 | Glaxo Group Limited | Pyrazolopyridine derivatives |
US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
NZ540730A (en) | 2002-12-24 | 2010-09-30 | Rinat Neuroscience Corp | Anti-NGF antibodies and methods using same |
WO2004098528A2 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amine compounds useful as kinase inhibitors |
NZ599196A (en) | 2003-07-15 | 2014-01-31 | Amgen Inc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
WO2005030128A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Pyrazole modulators of metabotropic glutamate receptors |
US20050143384A1 (en) | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
US20070185152A1 (en) * | 2004-03-02 | 2007-08-09 | Smithkline Beecham Corporation | Inhibitors of akt activity |
JP2007535565A (ja) | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | 癌の治療に有用な置換ピラゾリル尿素誘導体 |
AU2006215394B2 (en) | 2005-02-16 | 2009-10-08 | Astrazeneca Ab | Chemical compounds |
WO2006115452A1 (en) | 2005-04-27 | 2006-11-02 | Astrazeneca Ab | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
AU2006248780B2 (en) | 2005-05-16 | 2010-06-03 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
ZA200800901B (en) * | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
AU2006301458A1 (en) | 2005-10-13 | 2007-04-19 | Devgen N.V. | Kinase inhibitors |
WO2007069773A1 (en) | 2005-12-15 | 2007-06-21 | Shionogi & Co., Ltd. | A pharmaceutical composition comprising an amide derivative |
EA200900072A1 (ru) | 2006-07-07 | 2009-06-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Фенилзамещенные гетероарильные производные и их применение в качестве противоопухолевых средств |
US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
JP5735799B2 (ja) | 2007-04-06 | 2015-06-17 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | ゴナドトロピン放出ホルモン受容体拮抗薬およびそれに関連する方法 |
GB0708188D0 (en) * | 2007-04-27 | 2007-06-06 | Merck Sharp & Dohme | Therapeutic compounds |
BRPI0811065A2 (pt) * | 2007-06-08 | 2014-12-02 | Abbott Lab | Indazóis 5-heteroaril substituídos como inibidores de quinase |
CL2008001943A1 (es) | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
EP2176249A2 (en) | 2007-07-02 | 2010-04-21 | Boehringer Ingelheim International GmbH | New chemical compounds |
SI2176231T1 (sl) * | 2007-07-20 | 2017-01-31 | Nerviano Medical Sciences S.R.L. | Substituirani indazolni derivati, aktivni kot kinazni inhibitorji |
US8236824B2 (en) | 2007-10-09 | 2012-08-07 | MERCK Patent Gesellschaft mit beschränkter Haftung | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators |
CA2738026C (en) | 2008-09-22 | 2017-01-24 | Array Biopharma Inc. | Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors |
US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
KR101048448B1 (ko) * | 2008-11-21 | 2011-07-11 | 한국화학연구원 | 신규 피라졸로[4,3-b]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
RU2016116516A (ru) | 2008-12-08 | 2018-12-07 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
WO2010111653A2 (en) | 2009-03-27 | 2010-09-30 | The Uab Research Foundation | Modulating ires-mediated translation |
WO2011014775A1 (en) * | 2009-07-31 | 2011-02-03 | The Brigham And Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
CN106866667B (zh) * | 2009-11-05 | 2019-11-15 | 圣母大学 | 咪唑并[1,2-a]吡啶类化合物及其合成及使用方法 |
EP2588475B1 (en) | 2010-07-02 | 2015-05-20 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
EP2611784A4 (en) * | 2010-08-05 | 2014-01-08 | Amgen Inc | BENZIMIDAZOLE AND AZABENEZIMIDAZOLE COMPOUNDS FOR INHIBITING THE ANAPLASTIC LYMPHOMINE KINASE |
WO2012028579A1 (de) | 2010-09-01 | 2012-03-08 | Bayer Cropscience Ag | N-(tetrazol-5-yl)- und n-(triazol-5-yl)arylcarbonsäureamide und ihre verwendung als herbizide |
KR20130141500A (ko) * | 2010-09-29 | 2013-12-26 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
US9079859B2 (en) | 2011-01-21 | 2015-07-14 | Auckland Uniservices Limited | Synthetic lethal targeting of glucose transport |
EP2673270A1 (en) | 2011-02-09 | 2013-12-18 | Syngenta Participations AG | Insecticidal compounds |
KR101960555B1 (ko) | 2011-05-13 | 2019-03-20 | 어레이 바이오파마 인크. | Trka 키나제 저해제로서의 피롤리디닐 유레아 및 피롤리디닐 티오유레아 화합물 |
JP6050335B2 (ja) | 2011-05-23 | 2016-12-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | チアゾール誘導体 |
CN102796103A (zh) | 2011-05-23 | 2012-11-28 | 南京英派药业有限公司 | 6-(芳基甲酰)咪唑并[1,2-a]嘧啶和6-(芳基甲酰)[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用 |
WO2013009582A1 (en) * | 2011-07-12 | 2013-01-17 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
AU2012339753A1 (en) * | 2011-11-14 | 2014-06-19 | Tesaro, Inc. | Modulating certain tyrosine kinases |
WO2013088257A1 (en) * | 2011-12-12 | 2013-06-20 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic compounds as tropomyosin receptor kinase a (trka) inhibitors |
EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
TWI652014B (zh) * | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
-
2014
- 2014-03-26 WO PCT/CN2014/074143 patent/WO2015143652A1/en active Application Filing
-
2015
- 2015-03-23 MX MX2016012481A patent/MX2016012481A/es unknown
- 2015-03-23 RU RU2016141645A patent/RU2016141645A/ru not_active Application Discontinuation
- 2015-03-23 RU RU2016141647A patent/RU2016141647A/ru not_active Application Discontinuation
- 2015-03-23 US US15/129,206 patent/US9862716B2/en active Active
- 2015-03-23 EP EP15769224.5A patent/EP3122345B1/en active Active
- 2015-03-23 AU AU2015236438A patent/AU2015236438A1/en not_active Abandoned
- 2015-03-23 MX MX2016012483A patent/MX2016012483A/es unknown
- 2015-03-23 KR KR1020167029495A patent/KR20160132114A/ko unknown
- 2015-03-23 WO PCT/US2015/022004 patent/WO2015148373A2/en active Application Filing
- 2015-03-23 CN CN201580027484.1A patent/CN106456582A/zh active Pending
- 2015-03-23 CN CN201580027483.7A patent/CN106456581A/zh active Pending
- 2015-03-23 US US15/128,793 patent/US9862707B2/en active Active
- 2015-03-23 JP JP2016558339A patent/JP2017508766A/ja active Pending
- 2015-03-23 CA CA2942957A patent/CA2942957A1/en not_active Abandoned
- 2015-03-23 CA CA2942817A patent/CA2942817A1/en not_active Abandoned
- 2015-03-23 KR KR1020167029497A patent/KR20160131119A/ko unknown
- 2015-03-23 EP EP15769051.2A patent/EP3122344B1/en active Active
- 2015-03-23 WO PCT/US2015/021952 patent/WO2015148354A2/en active Application Filing
- 2015-03-23 AU AU2015236363A patent/AU2015236363A1/en not_active Abandoned
- 2015-03-23 JP JP2016558347A patent/JP2017512786A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2016141647A (ru) | 2018-04-27 |
AU2015236363A1 (en) | 2016-09-01 |
CN106456582A (zh) | 2017-02-22 |
EP3122344A2 (en) | 2017-02-01 |
KR20160132114A (ko) | 2016-11-16 |
EP3122344B1 (en) | 2022-04-27 |
WO2015143652A8 (en) | 2015-12-10 |
EP3122344A4 (en) | 2017-09-06 |
RU2016141645A (ru) | 2018-04-27 |
US9862707B2 (en) | 2018-01-09 |
WO2015143652A1 (en) | 2015-10-01 |
RU2016141647A3 (es) | 2018-06-26 |
MX2016012481A (es) | 2016-12-16 |
WO2015148354A2 (en) | 2015-10-01 |
CA2942817A1 (en) | 2015-10-01 |
CA2942957A1 (en) | 2015-10-01 |
EP3122345A2 (en) | 2017-02-01 |
CN106456581A (zh) | 2017-02-22 |
WO2015148373A3 (en) | 2015-11-26 |
US9862716B2 (en) | 2018-01-09 |
EP3122345A4 (en) | 2017-10-04 |
JP2017512786A (ja) | 2017-05-25 |
US20170107204A1 (en) | 2017-04-20 |
EP3122345B1 (en) | 2020-12-16 |
JP2017508766A (ja) | 2017-03-30 |
RU2016141645A3 (es) | 2018-10-26 |
AU2015236438A1 (en) | 2016-09-01 |
US20170114056A1 (en) | 2017-04-27 |
WO2015148373A2 (en) | 2015-10-01 |
WO2015148354A3 (en) | 2015-12-03 |
KR20160131119A (ko) | 2016-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016012481A (es) | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. | |
MX2016012480A (es) | Inhibidores de quinasa a relacionada con tropomiosina (trka), composiciones y sus metodos. | |
WO2015042085A3 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
WO2015148350A3 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
WO2016164286A3 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
PH12017502050A1 (en) | Naphthyridine compounds as jak kinase inhibitors | |
SV2017005434A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
MX2018013191A (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
SG10201806846RA (en) | Cyclopropylamines as lsd1 inhibitors | |
GEP20227344B (en) | Pyrimidine compound as jak kinase inhibitor | |
CO2017005588A2 (es) | 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
NZ721057A (en) | Compositions of compounds and uses thereof | |
BR112017008039A2 (pt) | derivados de pirazol como inibidores de nik | |
GB2533454A (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
TW201613896A (en) | Novel 2,5-substituted pyrimidines | |
MX2017000524A (es) | Compuestos novedosos de pirimidina sustituida. | |
EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
BR112017007704A2 (pt) | derivados de pirazolopirimidina como inibidores de nik | |
MX2017000522A (es) | Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde. | |
SG10201900954SA (en) | Heterocycles as Modulators of Kinase Activity | |
MX2016010268A (es) | Pirimidinimidazolaminas como modulares de actividad de cinasa. |